Clinical trial
Study of the Impact of Neoadjuvant Therapy on the Heterogeneity of Triple Negative Breast Cancer Through Single-cell RNA Sequencing (scRNAseq) and Whole-exome Sequencing (WES)
NCT05807516 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of the Impact of Neoadjuvant Therapy on the Heterogeneity of Triple Negative Breast Cancer Through Single-cell RNA Sequencing (scRNAseq) and Whole-exome Sequencing (WES)
- Lead sponsor
- Regina Elena Cancer Institute
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- December 14, 2021
- Completion date
- December 31, 2024
- Enrollment
- 20 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.